Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of Clinical Cancer Researchё a journal of the American Association for Cancer Research.

Thousands of women die from breast cancer each year because current treatments are not always effective and in some cases fail to stem the disease, warns Breast Cancer Campaign today.

Hormone replacement therapy (HRT) for peri- and postmenopausal symptoms increases disease recurrence in breast cancer survivors, according to an article published online March 25 in the Journal of the National Cancer Institute.

The use of sentinel lymph node biopsy (SLNB) during breast cancer surgery increased substantially from 1998 through 2005, according to an article published online March 25 in the Journal of the National Cancer Institute.

It is well established that Id1, a gene normally produced only in embryonic development, is reactivated in many 'solid' cancers, or carcinomas.

Whether or not relatives talk about the family’s history of cancer significantly impacts attitudes and knowledge about genetic counseling and testing for those at moderate risk of developing breast cancer, according to a new preliminary study presented today at the American Society for Preventive Oncology meeting in Bethesda, Md.

Researchers at the University of Chicago are studying possible connections between living in disadvantaged neighborhoods and the development of early onset breast cancer in a path-breaking project led by Sarah Gehlert, Director of the Center for Interdisciplinary Health Disparities Research at the University.

In roughly five to ten percent of breast cancer cases there is a family history of breast cancer– i.e., hereditary and, thus, genetic factors play a role here. Alterations in the genes known as BRCAI and BRCAII are a major cause of familial breast cancer – these are responsible for roughly 25 percent of such cases.

Women with breast cancer have more aggressive disease and lower survival rates if they are overweight or obese, according to findings published in the March 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy.

Epigenetic regulation – modifications to the structure of chromatin that influence which genes are expressed in a cell – is a key player in embryonic development and cancer formation. Researchers at the European Molecular Biology Laboratory [EMBL] in Heidelberg now gained new insight into one crucial epigenetic mechanism and reveal that it acts much faster than assumed.

Researchers at the University of California, San Francisco have developed a way to quickly estimate a woman's risk for invasive breast cancer. The new model, based on a measure of breast density that is already reported with the majority of mammograms today, is the first to be validated across multiple ethnic groups living in the United States.